The USG Board of Regents decided against renaming more than 70 building across the university system last semester that are named after those who partook in slavery, oppression, anti-Semitism and supremacy.
Students and faculty have been informed by an email sent from the policy administration at Jan. 25 of the modifications made on the anti-harassment and non-discrimination policies.
VSU receives funding for new Performing Arts Center vsuspectator.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vsuspectator.com Daily Mail and Mail on Sunday newspapers.
IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma
- Darovasertib monotherapy results in 57% 1-year Overall Survival (OS) Rate in predominantly 2L / 3L and heavily pre-treated (out to 7L / 8L) MUM patients, where historical 1-year OS Rate has been reported at 37%
- Darovasertib monotherapy median Overall Survival in MUM is 13.2 months, where historical median OS has been reported at approximately 7 months
- Darovasertib and binimetinib combination reports 2 partial responses (PR), including one confirmed partial response, out of nine evaluable patients with at least 2 post-baseline scans (22%) in MUM; 1 PR patient (-40.5%) is awaiting a confirmatory scan